
Gastritis Explained: What It Is, What Causes It, and How to Treat It
When your stomach lining gets irritated, inflamed or damaged, that's gastritis. It's a broad term that covers many conditions, all involving inflammation of the gastric mucosa—the layer inside your stomach. But gastritis isn't a one-size-fits-all diagnosis. It can come on suddenly or creep in over time. It might have noticeable symptoms—or none at all.
While some types clear up quickly, others increase your risk for more serious issues, including gastric cancer. Let's break down what gastritis really is, the different types, why it happens and how it's diagnosed and treated. Table of Contents
Gastritis means inflammation of the stomach lining but the underlying causes, location of the inflammation and tissue damage can vary widely [2], [5]. Some types affect specific areas of the stomach while others are more widespread. The severity and duration also vary: some people get a mild, short-lived episode while others may develop chronic inflammation over years [6]. Gastritis depends on many factors including the underlying cause and severity of the condition.
Non-Atrophic vs. Atrophic Gastritis
Non-atrophic gastritis is usually linked to Helicobacter pylori (H. pylori) infection especially in younger people. It's less structurally damaging to the stomach lining. Helicobacter pylori infection is a common cause of non-atrophic gastritis.
Atrophic gastritis on the other hand involves the loss of gastric glandular cells and is often the result of long-standing H. pylori infection. This type is especially concerning because it's recognized as a major risk factor for gastric cancer [2]. Long-term gastritis can impair the stomach's ability to absorb essential nutrients including folic acid leading to serious health issues such as anemia and other complications.
Acute vs. Chronic Gastritis
Acute gastritis happens suddenly. It can be triggered by alcohol, medications like NSAIDs or stress. Anti-inflammatory medication can also be a trigger and should be stopped if possible. Symptoms usually resolve once the trigger is removed.
happens suddenly. It can be triggered by alcohol, medications like NSAIDs or stress. Anti-inflammatory medication can also be a trigger and should be stopped if possible. Symptoms usually resolve once the trigger is removed. Chronic gastritis develops over time and may be asymptomatic. But left untreated it can lead to more serious complications including ulcers and cancer. Untreated chronic gastritis can also result in a bleeding ulcer which occurs when the stomach lining is severely compromised.
H. pylori is the most common cause of gastritis worldwide. In fact it's found in the majority of patients with stomach inflammation and is particularly prevalent in children [3], [7]. This bacterium disrupts the protective mucus layer in the stomach allowing acid to irritate the tissue. Tests for helicobacter pylori bacteria are essential for confirming the presence of gastritis. Pylori bacteria are found in a significant portion of the population.
Gastritis isn't just about H. pylori. Several other factors can damage the stomach lining: Autoimmune Gastritis – The immune system mistakenly attacks stomach cells, interfering with vitamin B12 absorption and possibly leading to pernicious anemia [5] , [9] .
– The immune system mistakenly attacks stomach cells, interfering with vitamin B12 absorption and possibly leading to pernicious anemia . Acute Erosive Gastritis – Often triggered by severe physical stress, critical illness or direct chemical injury from substances like alcohol or NSAIDs.
– Often triggered by severe physical stress, critical illness or direct chemical injury from substances like alcohol or NSAIDs. Celiac Disease and Food Allergies – Immune responses to gluten or other allergens can also trigger gastric inflammation.
– Immune responses to gluten or other allergens can also trigger gastric inflammation. Crohn's Disease – This inflammatory bowel condition can extend to the stomach.
– This inflammatory bowel condition can extend to the stomach. Iatrogenic Gastritis – Newer cancer therapies have been associated with unique patterns of drug-induced gastritis [4] .
– Newer cancer therapies have been associated with unique patterns of drug-induced gastritis . Major Surgery – Significant physiological stress from major surgery can lead to reduction in blood supply to the digestive system making the stomach lining more susceptible to damage and inflammation.
– Significant physiological stress from major surgery can lead to reduction in blood supply to the digestive system making the stomach lining more susceptible to damage and inflammation. Medical History – Reviewing a patient's medical history is important for diagnosing gastritis as it helps doctors understand the patient's personal and family medical background.
Gastritis symptoms can vary widely from person to person but some common signs include stomach pain, bloating, nausea, vomiting and feeling full after eating. Acute gastritis often presents with severe symptoms such as intense stomach pain and vomiting blood which can be alarming. Chronic gastritis on the other hand may develop gradually and cause milder but persistent discomfort. Symptoms of chronic gastritis can include dull ache in the upper abdomen, feeling full after eating small amounts and ongoing nausea.
In some cases gastritis may not cause any symptoms until significant damage has occurred to the stomach lining. This can allow stomach acids and enzymes to cause further irritation and damage. Consuming too much alcohol or certain foods can exacerbate gastritis pain so it's important to identify and avoid these triggers. If left untreated gastritis can lead to more serious complications such as stomach ulcers, bleeding and scarring of the stomach lining. So if you have persistent or worsening symptoms seek medical attention.
You can't diagnose gastritis based on symptoms alone. Some people don't feel a thing while others may have nausea, bloating or pain. The gold standard for diagnosis is endoscopy where a thin tube with a camera is used to view the stomach lining. Doctors will take biopsies for histological analysis so they can see what's happening at the microscopic level [5].
Blood tests are necessary for confirming diagnoses such as anemia and detecting infections like H. pylori. A stool test is a reliable method to confirm the presence of H. pylori. A breath test can also be used to screen for H. pylori infection. Upper endoscopy is a critical diagnostic procedure for assessing stomach conditions.
Gastritis is often classified using formal systems that help doctors determine severity and risks: Sydney System – Considers the cause, location and appearance of inflammation [6] .
– Considers the cause, location and appearance of inflammation . OLGA Staging – Short for Operative Link on Gastritis Assessment, this system correlates biopsy results with long term cancer risk [2]. These systems help assess changes in the gastric mucosa and guide treatment decisions.
These classifications aren't just academic – they help guide treatment and surveillance.
This type is marked by small bumps or nodules on the stomach lining, typically in the antrum (lower part of the stomach). It's common in younger patients and linked to H. pylori. Symptoms may include epigastric pain, nausea or bloating [1]. Stomach discomfort is also a common symptom, often after eating and may involve nausea and vomiting. Reactive Gastropathy – Caused by bile reflux or NSAIDs.
– Caused by bile reflux or NSAIDs. Lymphocytic Gastritis – Increase in lymphocytes in the stomach lining.
– Increase in lymphocytes in the stomach lining. Eosinophilic Gastritis – High number of eosinophils (a type of white blood cell) and may be related to allergies or autoimmune disease [10]. Inflammatory changes can extend to the small intestine, particularly the duodenum, indicating a broader impact on the digestive system.
Untreated gastritis can cause stomach ulcers, potentially leading to pain and life-threatening bleeding or perforation. Chronic gastritis, especially with H. pylori, elevates stomach cancer risk and can cause digestive disorders [11]. It may also contribute to autoimmune conditions like pernicious anemia and increase the risk of kidney disease. Seek medical help for persistent symptoms. Treatment, including proton pump inhibitors and other medications, depends on the cause and severity, but timely intervention can prevent complications and improve health.
There's no one size fits all treatment. Management depends on the root cause. Anti-nausea medications can be used to alleviate nausea associated with gastritis. The stomach needs to produce acid for digestion but excessive acid can worsen inflammation [8].
H. pylori Eradication
When H. pylori is involved triple therapy—usually a proton pump inhibitor (PPI) plus two antibiotics—is the way to go. This clears the infection and reverses inflammation and reduces long term cancer risk [1]. A breath sample can be used to confirm the presence of H. pylori where the patient swallows a urea substance that the bacteria metabolize and produces carbon dioxide which is detected in the breath sample.
Other Therapies
Autoimmune Gastritis may require vitamin B12 supplementation.
may require vitamin B12 supplementation. Drug-induced Gastritis often improves once the offending medication is stopped.
often improves once the offending medication is stopped. Dietary Support – A growing body of research suggests that certain foods and food-derived compounds may help manage gastritis by soothing the stomach lining and reducing inflammation [12]. These foods can also support the digestive system and overall digestive health.
Gastritis isn't just one disease—it's a spectrum of stomach inflammation with many causes and outcomes. H. pylori is the most common trigger but autoimmune conditions, medications and even food sensitivities can play a role.
With proper diagnosis using endoscopy and biopsy gastritis can often be treated—and in many cases reversed. The key is to get to the root of the inflammation and tailor treatment accordingly.
Understanding the digestive tract and the lining of the stomach is crucial for managing gastritis. As research evolves especially around diet-based interventions the future of gastritis care looks more personalized and promising.
[1] Dwivedi, M., Misra, S. P., & Misra, V. (2008). Nodular gastritis in adults: clinical features, endoscopic appearance, histopathological features, and response to therapy. Journal of gastroenterology and hepatology, 23(6), 943–947. https://doi.org/10.1111/j.1440-1746.2007.05044.x
[2] Rugge, M., Pennelli, G., Pilozzi, E., Fassan, M., Ingravallo, G., Russo, V. M., Di Mario, F., Gruppo Italiano Patologi Apparato Digerente (GIPAD), & Società Italiana di Anatomia Patologica e Citopatologia Diagnostica/International Academy of Pathology, Italian division (SIAPEC/IAP) (2011). Gastritis: the histology report. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 43 Suppl 4, S373–S384. https://doi.org/10.1016/S1590-8658(11)60593-8
[3] Glickman, J. N., & Antonioli, D. A. (2001). Gastritis. Gastrointestinal endoscopy clinics of North America, 11(4), 717–vii. https://pubmed.ncbi.nlm.nih.gov/11689363/
[4] Pennelli, G., Grillo, F., Galuppini, F., Ingravallo, G., Pilozzi, E., Rugge, M., Fiocca, R., Fassan, M., & Mastracci, L. (2020). Gastritis: update on etiological features and histological practical approach. Pathologica, 112(3), 153–165. https://doi.org/10.32074/1591-951X-163
[5] Rugge, M., Savarino, E., Sbaraglia, M., Bricca, L., & Malfertheiner, P. (2021). Gastritis: The clinico-pathological spectrum. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 53(10), 1237–1246. https://doi.org/10.1016/j.dld.2021.03.007
[6] Chen, M. Y., Ott, D. J., Clark, H. P., & Gelfand, D. W. (2001). Gastritis: classification, pathology, and radiology. Southern medical journal, 94(2), 184–189. https://pubmed.ncbi.nlm.nih.gov/11235032/
[7] Kayaçetin, S., & Güreşçi, S. (2014). What is gastritis? What is gastropathy? How is it classified?. The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 25(3), 233–247. https://doi.org/10.5152/tjg.2014.7906
[8] Muszyński, J., Ziółkowski, B., Kotarski, P., Niegowski, A., Górnicka, B., Bogdańska, M., Ehrmann-Jóśko, A., Zemlak, M., Młynarczyk-Bonikowska, B., & Siemińska, J. (2016). Gastritis - facts and doubts. Przeglad gastroenterologiczny, 11(4), 286–295. https://doi.org/10.5114/pg.2016.57793
[9] Varbanova, M., Frauenschläger, K., & Malfertheiner, P. (2014). Chronic gastritis - an update. Best practice & research. Clinical gastroenterology, 28(6), 1031–1042. https://doi.org/10.1016/j.bpg.2014.10.005
[10] Owen D. A. (2003). Gastritis and carditis. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 16(4), 325–341. https://doi.org/10.1097/01.MP.0000062995.72390.14
[11] Bacha, D., Walha, M., Ben Slama, S., Ben Romdhane, H., Bouraoui, S., Bellil, K., & Lahmar, A. (2018). Chronic gastritis classifications. La Tunisie medicale, 96(7), 405–410. https://pubmed.ncbi.nlm.nih.gov/12692198/
[12] Duque-Buitrago, L. F., Tornero-Martínez, A., Loera-Castañeda, V., & Mora-Escobedo, R. (2023). Use of food and food-derived products in the treatment of gastritis: A systematic review. Critical reviews in food science and nutrition, 63(22), 5771–5782. https://doi.org/10.1080/10408398.2021.2024131

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
a day ago
- Medscape
NSAIDs May Pose Greater Heart Risks Than Colchicine in Gout
In patients with gout starting allopurinol as a long-term urate-lowering therapy, the prophylactic use of nonsteroidal anti-inflammatory drugs (NSAIDs) was associated with a higher risk for major adverse cardiovascular events (MACEs) than the use of colchicine or no prophylaxis. METHODOLOGY: Researchers followed a target trial framework to emulate a randomized clinical trial using data from administrative databases in British Columbia, Canada, to compare the cardiovascular safety of the prophylactic use of NSAIDs vs colchicine in patients with gout who started allopurinol between 1995 and 2022. They included 9060 patients who were prescribed NSAIDs (mean age, 60.9 years; 83.5% men) who were propensity score-matched with 9060 patients prescribed colchicine on the same day as allopurinol. The primary outcome was MACE, a composite of myocardial infarction, ischemic stroke, or cardiovascular death. Secondary outcomes included the individual components of MACE and all-cause mortality. Sensitivity analyses were also conducted with follow-up truncated after 3 months or 6 months and using inverse probability treatment weighting. Additionally, the cardiovascular safety of NSAIDs and colchicine was compared with that of no prophylaxis after propensity matching. TAKEAWAY: The risk for MACE was higher in patients using NSAIDs than in those using colchicine (hazard ratio [HR], 1.56; 95% CI, 1.11-2.17). Findings were consistent in sensitivity analyses. The use of NSAIDs was associated with significantly higher risks for cardiovascular death (HR, 2.50; 95% CI, 1.14-5.26) and all-cause mortality (HR, 2.00; 95% CI, 1.19-3.45) than the use of colchicine. Compared with no prophylaxis, the use of NSAIDs was associated with a 50% higher risk for MACE (HR, 1.50; 95% CI, 1.17-1.91) and a 93% higher risk for myocardial infarction (HR, 1.93; 95% CI, 1.35-2.75), whereas the use of colchicine was not associated with risk for MACE or its individual components. IN PRACTICE: 'The findings of this present study have the potential to impact clinical care as well as current guidelines, as they highlight the real potential dangers of NSAID use, even short-term, among patients with gout and provide additional evidence in support of colchicine as the preferred paradoxical gout flare prophylaxis agent,' the authors wrote. SOURCE: This study was led by Chio Yokose, MD, MSc, Massachusetts General Hospital, Boston. It was published online on May 26, 2025, in Arthritis & Rheumatology . LIMITATIONS: The risk for residual confounding factors remained owing to the observational nature of this study. Data on key cardiovascular risk factors such as use of tobacco, BMI, or lipid panel were unavailable. Cardiovascular risk associated with different types of NSAID was not analyzed. DISCLOSURES: Some authors reported receiving support from the National Institutes of Health and the Canadian Institutes of Health Research. Several authors reported receiving personal fees, consulting fees, royalties, and grants, and having board positions and other financial ties with multiple pharmaceutical and healthcare companies.


Health Line
3 days ago
- Health Line
The Link Between Ibuprofen and Ulcers
Long-term ibuprofen use can increase your risk of bleeding and ulcers in your stomach and intestines. If you take ibuprofen regularly, you can take steps to prevent peptic ulcers and protect stomach health. Peptic ulcers are slow-healing sores that can develop in your stomach lining, the beginning or top part of your small intestines (duodenum), or your esophagus. If you have a peptic ulcer, you'll usually experience some degree of abdominal pain. This pain can range from mild to severe and tends to come and go. Some people describe this pain as dull, while for others, it has more of a burning sensation. You might feel this pain anywhere from your belly button to your chest. Other symptoms include: Peptic ulcers can develop for a few reasons. One common cause is the frequent use of nonsteroidal inflammatory drugs (NSAIDs), including ibuprofen (Advil), naproxen (Aleve), and aspirin. Another is infection. Read on to learn how ibuprofen affects your stomach and what you can do to lower your risk of ulcers. Can ibuprofen cause stomach ulcers? Your body produces hormones called prostaglandins, which help heal tissue damage and injury, play a role in ovulation and labor, and help gut muscles contract and relax. These hormones also benefit your stomach in two main ways. They help repair and heal any damage to the lining of your stomach. They also protect your stomach from damage through the production of stomach mucus, which helps counter the effects of the stomach acid that helps break down your food. Stomach acid is very strong — strong enough to wear down your teeth and bones. If your body doesn't produce enough prostaglandins, this acid can easily damage your stomach lining. This is where ibuprofen and other NSAIDs can pose a danger. If you have an infection or injury, your body produces prostaglandins to help you heal. In some cases, though, your body may produce too much of these hormones. High levels of prostaglandins can lead to pain, swelling, and other inflammation. Ibuprofen relieves these symptoms by reducing the amount of prostaglandins your body can produce. But over time, the drop in prostaglandins can leave your stomach more vulnerable to damage. Ulcers don't develop overnight You probably won't develop an ulcer after taking ibuprofen for a few days in a row. Still, regular doses of ibuprofen daily for weeks or months will increase your chances of developing a peptic ulcer. take ibuprofen with other NSAIDs take ibuprofen with some other medications, such as corticosteroids, blood thinners, serotonin-norepinephrine reuptake inhibitors (SNRIs), or selective serotonin reuptake inhibitors (SSRIs) have a history of stomach ulcers have an H. pylori infection are older than 65 have three or more servings of alcohol a day smoke cigarettes Reducing your risk Most people can safely take ibuprofen to relieve short-term symptoms, such as fever, menstrual cramps, or body aches and pains. When taking ibuprofen or any other medication, you can reduce your risk of unwanted side effects by reading the label and following the directions closely. These tips can also help lower your chances of developing an ulcer: Take the smallest possible dose: Does your medication bottle say, 'Take 1 to 2 tablets every 4 to 6 hours?' It never hurts to start with one tablet and pay attention to your symptoms before taking more. Avoid taking too many doses: When taking ibuprofen around the clock to relieve pain that remains for a few days, like menstrual cramps, it may help to set a timer for each dose. If you take your next dose too soon, you may take more ibuprofen than planned and exceed the daily recommendation. Take ibuprofen for no more than a few days at a time: If you have persistent fever, aches, or other symptoms, it may be worth asking your healthcare professional about other options for treating your pain. Keep in mind, too, that NSAIDs to treat migraine pain and other headaches could lead to medication overuse headaches. Medications that help prevent peptic ulcers Many people take ibuprofen regularly to treat arthritis and other conditions that cause chronic pain and inflammation. If you need to take an NSAID long term, consider asking your doctor about medication to help protect against ulcers. The following medications could make a difference: proton pump inhibitors (PPIs), which help lower stomach acid production H2 blockers, which also help lower stomach acid production misoprostol, which helps boost the production of stomach mucus These medications may not work well for everyone and may cause some side effects, including constipation and diarrhea. Also, long-term use of PPIs may increase your risk of fractures and infection. Your care team can offer more guidance on whether these medications are a good option for you. Bottom line Most people won't get an ulcer from taking ibuprofen occasionally, especially when sticking to the dosing directions on the label. Taking several doses of ibuprofen a day for a few weeks or longer may raise your risk of peptic ulcers, especially if you take other NSAIDs at the same time. If you use ibuprofen to manage ongoing pain and inflammation, a good next step involves asking a doctor about medications that can lower your ulcer risk. They can also offer more guidance on other options for pain relief.


Medscape
7 days ago
- Medscape
Anemia in a Heavy Smoker
Editor's Note: The Case Challenge series includes difficult-to-diagnose conditions, some of which are not frequently encountered by most clinicians, but are nonetheless important to accurately recognize. Test your diagnostic and treatment skills using the following patient scenario and corresponding questions. If you have a case that you would like to suggest for a future Case Challenge, please email us at ccsuggestions@ with the subject line "Case Challenge Suggestion." We look forward to hearing from you. Background and Initial Presentation A 40-year-old man presents to the emergency department with complaints of repeated vomiting and dizziness for the past 2 days. He has no fever or diarrhea. He has been experiencing dyspepsia and abdominal fullness after meals for a month. These symptoms have increased during this time, causing him to decrease his food intake week by week. He has tried over-the-counter drugs, such as antacids and pantoprazole, with no effect. This condition has been associated with epigastric pain; his general practitioner tested him for Helicobacter pylori , which was negative. The patient has been a heavy smoker for the past 15 years, smoking one pack per day. Since his symptoms began, he has tried to quit smoking using nicotine patches. He attributed his dyspepsia to the use of the nicotine patch, considering his negative H pylori test. He therefore decreased the duration of his nicotine patch use, but his symptoms only minimally improved. He has also experienced easy fatigability over the past 4 months. He noted that at times during the previous month, his eyes have become yellow. His family history shows that his father died of colon cancer in his 50s. The patient's presentation is suspicious for hemolytic anemia, so it will be important to confirm this with a Coombs test and a peripheral blood smear for schistocytes.[1] ESR and CRP and GGT levels will not help diagnose the cause of hemolytic anemia. Physical Examination and Workup Examination: Blood pressure: 100/60 mm Hg Pulse: 95 beats/min Temperature: 37.5 °C (99.5 °F) General examination: Pallor of the inner lips; hand creases apparent, not faded Abdominal examination: Splenomegaly Laboratory investigations: Sodium: 130 mEq/L (range, 135-145) Potassium: 3 mEq/L (range, 3.5-5.2) Creatinine: 1.5 mg/dl (range, 0.7-1.3) Blood urea nitrogen: 50 mg/dL (range, 6-24) Coombs test: 3+ (range, 0-4) Hemoglobin: 9 g/dL (range for men, 13.2-16.6) Calcium level: 9 mg/dL (range, 8.5-10.2) Complete blood film shows schistocytes count of 6% (range, normal is < 0.5%, although usual values are < 0.2%) Mean corpuscular volume: 90 fl (range, 80-100) Platelet: 150,000/µL (range, 150,000-450,000) White blood cells: 6000/µL (range, 4,500-11,000) ESR: 120 mm/hr (range for men, < 50 years old: < 15) CRP: 70 mg/dL (range, < 0.3) A CT of the abdomen with contrast was taken, showing the lesions in Figure 1. Figure 1. Abdominal CT with contrast showing lesions. MAHA as a paraneoplastic syndrome in infiltrative gastric cancer is the most likely diagnosis. MAHA as a paraneoplastic syndrome is a rare presentation of metastatic gastric cancer, with only about 50 cases documented in the literature. MAHA is caused by tumor-associated thrombotic microangiopathy and is considered an oncologic emergency.[2] It is associated with poor prognosis.[3] In one single-center analysis, most of the patients with MAHA showed infiltrative diffuse gastric cancer with partial or complete signet ring cellular morphology. All patients had metastatic disease at the time of presentation of MAHA, either at first diagnosis or recurrence.[2] Gastric cancer (GC) is a major cause of cancer-related deaths, mostly due to diagnosis at advanced stages of the disease;[4] it is often asymptomatic in the early stages.[5] Asymptomatic cancers can present with nonspecific paraneoplastic symptoms such as anemia or endocrine disturbances. Rapid development of pernicious anemia due to adenocarcinoma of the stomach has been reported in the literature.[6] Advanced GC symptoms may include iron deficiency anemia.[5] Anemia due to bleeding in cancers presents as microcytic anemia with low iron and ferritin levels (although ferritin can be elevated as part of the immune response to cancer).[7] Anemia due to malabsorption is usually due to deficiencies of B12 or folate causing macrocytic anemia or to iron malabsorption causing microcytic anemia.[7,8] In this patient, the Coombs test result was positive for hemolytic anemia, and the blood smear indicated elevated schistocytes. His anemia is normocytic hemolytic anemia due to destruction of the red blood cells with elevated lactate dehydrogenase and schistocytes. The presence of clear invasive GC provides a cause of his anemia. In the CT of the abdomen with contrast (Figure 1), circumferential wall thickening up to 15 mm was seen throughout the stomach. Multiple enlarged pathologic lymph nodes were noted perigastric, peripancreatic, within the porta-hepatis, and para-aortic. The largest was seen at porta hepatis measuring 30 x 14 mm. Mild ascites was present. The liver echo pattern was inhomogeneous with multiple bilobar hypodense non-enhancing hepatic focal lesions: one in segment VI/VII measuring 8 x 7 mm and the other in segment III subcapsular exophytic lesion measuring 14 x 12 mm. An upper GI endoscopy was performed and biopsies were taken. Endoscopy showed thickened mucosa of the stomach with decreased gastric rugae and volume (Figure 2). Figure 2. Upper GI endoscopy showing thickened stomach mucosa with decreased gastric rugae and volume. The pathology report of the gastric antral biopsies showed diffuse signet ring cellular morphology stage III. Of note, in all newly diagnosed patients with GC, testing for microsatellite instability (MSI) status by PCR/next-generation sequencing or mismatch repair status by immunohistochemistry is recommended.[4] Testing for MSI status also should be done in patients with locally advanced and unresectable or metastatic GC to tailor treatment.[5] Signet ring cell cancer grade 3 usually shows recurrence within 2 years after standard treatment of radical surgery and chemotherapy. Signet ring cell cancer is often chemoresistant; even the use of adjuvant chemotherapy is controversial.[9] Adequate surgical resection is considered the main therapeutic option for signet ring cell GC;[10] surgery is recommended for appropriate metastatic GC candidates.[4] Advanced GC signet ring cell type is treated with 5-fluorouracil (5-FU);[11] for stage III, the treatment regimen is chemotherapy with a 5-FU-based combination.[2] For patients who are candidates for treatment with PD-1 inhibitors, PD-L1 testing may be considered. A specimen with a combined positive score ≥ 1 is viewed as exhibiting PD-L1 expression.[4] The patient was referred to surgery for a radical gastrectomy. After 1 month, he started chemotherapy with a 5-FU-based combination. After completing his 13-month course of chemotherapy, the patient began to experience cough and dyspnea. He presented to the emergency department with cyanosis and severe dyspnea. On examination, his temperature was normal but his oxygen saturation was 70%, and there was decreased air entry on both sides of the chest. A chest radiograph demonstrated bilateral pleural effusion. Chest CT with contrast was performed to exclude metastasis (Figure 3). The chest CT showed bilateral encysted pleural effusion with mild pericardial effusion. The lungs exhibited areas of atelectasis in relation to the effusion. Lung biopsies confirmed metastasis. Figure 3. Chest CT with contrast showing bilateral encysted pleural effusion. The findings indicated recurrence with metastatic presentation. Because of the late stage of disease and the type of tumor, the oncologist recommended personalized palliative immunotherapy to prolong survival and improve the patient's general condition. Immunotherapy options for GC include immunomodulators, checkpoint inhibitors,[4,5,12] and vaccines targeting the tumor.[12] The patient has recurrent disease following treatment with a 5-FU-containing regimen, and he had received a radical gastrectomy when he presented at stage III. His dyspnea is considered a rare presentation of GC, although it can occur in cases of pulmonary metastasis, pulmonary lymphangitic carcinomatosis, or pulmonary tumor thrombotic microangiopathy.[13] Immunotherapy for signet ring cell GC includes immune checkpoint inhibitors targeting PD-1 and PD-L1. In selected cases of signet ring cell cancer, where MSI is high with deficient mismatch repair proteins, immunotherapy with PD-1 could be effective.[10] PD-1 and PD-L1 checkpoint inhibitors decrease T-cell tolerance to the tumor cells, enhancing the body's adaptive immune response against cancer cells.[12] This patient had high MSI and started PD-1 inhibitor immunotherapy. His pulmonary symptoms improved, with decreased dyspnea and fatigue and increased oxygen saturation. Later chest CT showed absence of pleural effusion and pericardial effusion, and the metastatic nodules regressed. Signet ring cell GC comprises about 17% of primary gastric tumors.[14,15] Patients with signet ring cell gastric carcinoma usually exhibit higher TNM staging at presentation as compared with patients with non-signet ring cell tumors.[15] More patients with signet cell GC receive chemotherapy than those with non-signet cell cancer. Bone metastasis was higher in patients with signet ring cell cancer as compared with those with non-signet ring cell cancer GC in a large cohort (> 36,000) of GC patients.[15] First-line treatment for stage IV signet ring cell cancer includes palliative chemotherapy with docetaxel-5-FU-oxaliplatin. If the patient has stage IV disease at diagnosis, radical gastrectomy with chemotherapy (13 months) provides longer survival than chemotherapy alone (7 months).[14] However, in the REGATTA trial, palliative gastrectomy in stage IV disease did not provide any survival benefit over chemotherapy alone.[16] PD-1 inhibitor immunotherapy may be effective in patients with signet ring cell cancer with high MSI and deficient tumor mismatch repair.[10] As noted previously, PD-1 and PD-L1 checkpoint inhibitors decrease T-cell tolerance to the tumor cells, enhancing the body's adaptive immune response against cancer cells.[12] Although the patient's chest CT showed bilateral pleural effusion, that is not a prognostic marker for PD-1 inhibitor response. As noted earlier, signet ring cell cancer is often chemoresistant, and grade 3 usually shows recurrence within 2 years after the standard treatment of radical surgery and chemotherapy,[17] neither of which are prognostic markers for PD-1 inhibitor response.